Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.400 GeneticVariation phenotype BEFREE As a result, the ABCC2 rs3740065 genotype, sex, and the baseline level of alanine aminotransferase are independent risk factors of antituberculosis drug-induced hepatotoxicity, with P values of .008, .014, and <.001, respectively. 31648372 2020
Entrez Id: 1571
Gene Symbol: CYP2E1
CYP2E1
0.400 GeneticVariation phenotype BEFREE Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST. 31697922 2020
Entrez Id: 406906
Gene Symbol: MIR122
MIR122
0.400 Biomarker phenotype BEFREE However, miR-122-5p, -192-5p, -34a-5p and -22-3p demonstrated a much more significant induction in patients with hepatocellular DILI, thus revealing better specificity for hepatocellular damage. 31198949 2020
Entrez Id: 1571
Gene Symbol: CYP2E1
CYP2E1
0.400 AlteredExpression phenotype BEFREE Increased expression of CYP2E1 may represent the main factor contributing to oxidative stress-mediated liver damage in drug-induced liver injury (DILI). 31468699 2020
Entrez Id: 2952
Gene Symbol: GSTT1
GSTT1
0.390 GeneticVariation phenotype BEFREE Patients with the CYP2E1 variant genotype or Null GSTT1 showed higher risk of presenting DILI (p=0.09; OR: 4.57; 95% CI: 0.75-27.6). 31697922 2020
Entrez Id: 1244
Gene Symbol: ABCC2
ABCC2
0.360 GeneticVariation phenotype BEFREE As a result, the ABCC2 rs3740065 genotype, sex, and the baseline level of alanine aminotransferase are independent risk factors of antituberculosis drug-induced hepatotoxicity, with P values of .008, .014, and <.001, respectively. 31648372 2020
Entrez Id: 4363
Gene Symbol: ABCC1
ABCC1
0.310 GeneticVariation phenotype BEFREE Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. 31648372 2020
Entrez Id: 8647
Gene Symbol: ABCB11
ABCB11
0.100 Biomarker phenotype BEFREE Incorporating other mechanisms (reactive metabolite and cytotoxic metabolite generation and hepatic efflux transport inhibition, other than BSEP) to the HRM had minimal beneficial impact in DILI prediction/stratification. 31532188 2020
Entrez Id: 8647
Gene Symbol: ABCB11
ABCB11
0.100 Biomarker phenotype BEFREE We present a quantitative and mechanistic risk assessment for candidate nomination using data from <i>in vitro</i> assays (hepatic spheroids, BSEP, mitochondrial toxicity, and bioactivation), together with physicochemical (cLogP) and exposure (Cmax<sub>total</sub>) variables from a chemically diverse compound set (33 no/low-, 40 medium-, and 23 high-severity DILI compounds). 31535850 2020
Entrez Id: 124
Gene Symbol: ADH1A
ADH1A
0.010 Biomarker phenotype BEFREE Interestingly, further experiments with serum from rats with bile duct ligation (BDL)-induced liver disease indicated that Aldh1a1 and Adh1 are not detectable in serum in cholestasis and may therefore be specific for hepatocellular injury and possibly even drug-induced liver injury (DILI), in particular. 31651977 2020
Entrez Id: 216
Gene Symbol: ALDH1A1
ALDH1A1
0.010 Biomarker phenotype BEFREE Interestingly, further experiments with serum from rats with bile duct ligation (BDL)-induced liver disease indicated that Aldh1a1 and Adh1 are not detectable in serum in cholestasis and may therefore be specific for hepatocellular injury and possibly even drug-induced liver injury (DILI), in particular. 31651977 2020
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.540 GeneticVariation phenotype BEFREE We found that rs12422149 of SLCO2B1, rs2032582_AT of ABCB1, rs2306283 of SLCO1B1 and rs4148323 of UGT1A1 exhibited a significant association with MMI-DILI; however, no significant difference existed after Bonferroni correction. 31240859 2019
Entrez Id: 10
Gene Symbol: NAT2
NAT2
0.400 GeneticVariation phenotype BEFREE Subset analysis of NAT2 acetylator status and severity grade confirmed these results in AT-DILI patients with more severe disease whereas fast and intermediate acetylator phenotypes were associated with a decreased AT-DILI risk. 31699005 2019
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.400 Biomarker phenotype BEFREE Using these data, we derived a novel parameter, P<sub>ALT</sub>  = ALT_AUC*Peak ALT<sup>0.18</sup> /10<sup>5</sup> ((IU/L)<sup>2</sup> *h), where AUC is area under the curve, that correlated well with hepatocyte loss estimates derived by DILIsym in patients with DILI due to six different hepatotoxic drugs. 30303523 2019
Entrez Id: 10
Gene Symbol: NAT2
NAT2
0.400 GeneticVariation phenotype BEFREE Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population. 31245212 2019
Entrez Id: 1571
Gene Symbol: CYP2E1
CYP2E1
0.400 Biomarker phenotype BEFREE Cytochrome P450 2E1 (CYP2E1) plays a vital role in drug-induced hepatotoxicity and cancers (e.g. lung and bladder cancer), since it is responsible for metabolizing a number of medications and environmental toxins to reactive intermediate metabolites. 31203697 2019
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.400 Biomarker phenotype BEFREE RUCAM criteria were defined as the gold standard, and the other two criteria were as follows: 1) ALT or aspartate aminotransferase (AST) levels greater than 5 × the ULN on two consecutive occasions and/or ALP levels greater than 2 × the ULN on two consecutive occasions [issued by DILI Network (DILIN)]; 2) ALT levels greater than 1 × the ULN on two consecutive occasions or ALT levels greater than 2 × the ULN [issued by the National Medical Products Administration (NMPA) of China]. 31379581 2019
Entrez Id: 3106
Gene Symbol: HLA-B
HLA-B
0.400 Biomarker phenotype BEFREE We found no HLA-B*57 association with DILI due to other isoxazolyl penicillins (n = 6) or amoxicillin (n = 15) and no significant non-HLA signals for any penicillin-related DILI. 30661239 2019
Entrez Id: 2944
Gene Symbol: GSTM1
GSTM1
0.400 GeneticVariation phenotype BEFREE Previous studies suggest that individuals who are homozygous-null at the GSTM1 or GSTT1 locus may have an increased risk of environmentally related cancers and drug-induced hepatotoxicity. 30471640 2019
Entrez Id: 406906
Gene Symbol: MIR122
MIR122
0.400 Biomarker phenotype BEFREE Conclusion: GLDH appears to be more useful than miR-122 in identifying DILI patients, and K18, OPN, and MCSFR are promising candidates for prediction of prognosis during an acute DILI event. 29357190 2019
Entrez Id: 10
Gene Symbol: NAT2
NAT2
0.400 GeneticVariation phenotype BEFREE Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population. 31066138 2019
Entrez Id: 1571
Gene Symbol: CYP2E1
CYP2E1
0.400 Biomarker phenotype BEFREE Volatile anaesthetics are known to cause drug-induced liver injury, a hepatotoxic reaction characterised by antibodies to trifluoroacetylated lipid and protein adducts and cytochrome p450 2E1. 30761577 2019
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.400 Biomarker phenotype BEFREE There was one reported case in which raised ALT occurred with raised bilirubin, meeting criteria for moderate drug-induced liver injury. 30620055 2019
Entrez Id: 3106
Gene Symbol: HLA-B
HLA-B
0.400 Biomarker phenotype BEFREE In the pilot study, the frequency of HLA-B*35:01 was 45.4% in PM-DILI patients compared with 2.7% in the Han Chinese population (odds ratio [OR], 30.4; 95% confidence interval [CI], 11.7-77.8; P = 1.9 × 10<sup>-10</sup> ). 30985007 2019
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.400 Biomarker phenotype BEFREE Changes in the serum alanine aminotransferase (ALT) concentrations after starting corticosteroid treatment were determined and compared between the DILI and AIH groups. 31319011 2019